These results are in agreement with our previous study showing that VEGF and iNOS inhibition represent promising approaches for targeting tumor vasculature and certain NOS inhibitors could potentially serve as experimental agents for the treatment of certain chemoresistant tumors, including prostate tumors [54]. The gene discussed is NOS2; the disease is prostate neoplasm.